Trial · NCT01340235
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
NCT01340235, Phase 3, Unknown, Centre Hospitalier Universitaire de Nice
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin. Trials, record NCT01340235. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01340235
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
- NCT number
- NCT01340235
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 8 participants, estimated
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Conditions
- Epidermolysis Bullosa
- Interventions
- Oral erythromycin
- First posted
- 2011-04-22
- Last updated
- 2011-10-14
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | number of patients with decrease of blisters' number of at least 20% after 3 months of treatment by oral erythromycin | at 3 months of treatment | Principal end point is evaluated at inclusion and after one month of treatment, 3 months of treatment and 2 months after the end of the treatment |
| Secondary | Secondary end points are : effect of 3 months of oral erythromycin on - Global tolerance of treatment. | at 3 months of treatment | For each patient and globally, the nature, the frequency and the severity of the various unwanted effects will be described on the duration of the study. |
| Secondary | Secondary end points are : effect of 3 months of oral erythromycin on - Involved area | at 3 months of treatment | These criteria will be analyzed in comparison with the values to the inclusion (M0). We shall try to estimate the obstinacy of an effect 2 months after the end of the treatment. |
| Secondary | Secondary end points are : effect of 3 months of oral erythromycin on - pruritus, | at 3 months of treatment | These criteria will be analyzed in comparison with the values to the inclusion (M0). We shall try to estimate the obstinacy of an effect 2 months after the end of the treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01340235
GET https://conductscience.org/api/trials/v1/NCT01340235/registered